Guidelines and Publications on breast cancer management
Guidelines
Link to the latest breast cancer treatment guidelines issued by:
Publications
Find out what clinical investigators are saying about FEMARA®.
Breast International Group (BIG) 1-98 Collaborative Group, Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer., New England Journal of Medicine, August 2009.
Crivellari et al. Letrozole compared with tamoxifen for elderly patients with endocrine responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol, April 2008.
Gluck S. The prevention and management of distant metastases in women with breast cancer. Cancer Invest, January 2007.
Mouridsen HT. Letrozole in advanced breast cancer: the PO25 trial. Breast Cancer Res Treat, February 2007. [Epub ahead of print]
Breast International Group (BIG) 1-98 Collaborative Group, A Comparison of letrozole and Tamoxifen in postmenopausal Women with Early Breast Cancer., New England Journal of Medicine, December 2005.
Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, November 2003.
To read about the significant benefits of FEMARA® in the initial adjuvant setting, click here.
FEMARA® is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.